Sildenafil May Curb Cancer Spread in 5 Million-Patient Study as Statins Strengthen Cholesterol Blockade
Updated
Updated · SciTechDaily · Aug 1
Sildenafil May Curb Cancer Spread in 5 Million-Patient Study as Statins Strengthen Cholesterol Blockade
3 articles · Updated · SciTechDaily · Aug 1
Summary
Weizmann-led research found sildenafil may hinder metastasis by cutting cancer cells’ access to cholesterol, a key material they need when leaving a primary tumor and colonizing distant organs.
PDE5 inhibition raised cGMP, which the team said binds a cholesterol-transport protein inside cells, leaving less cholesterol available and creating a shortage metastatic cancer cells appear especially sensitive to.
Mouse models, patient-derived cancer cells and roughly 20 years of records from about 5 million Clalit members all pointed in the same direction, with sildenafil use linked to better survival in cancer patients.
Statins appeared to amplify that effect by both limiting new cholesterol production and tightening the squeeze on existing cholesterol supplies, suggesting a potential combination strategy using already approved drugs.
The findings, published in Cancer Research, remain research-stage evidence but highlight how common non-cancer medicines and patients’ metabolic state could shape cancer outcomes.